Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients

Inclusion Criteria: * Pathologic diagnosis of non small cell lung cancer, Stage Ⅱ-ⅢA before treatment * EGFR Gene mutated * ECOG 0-1 * liver, kidney and bone marrow are functional healthy，WBC\>4.0×109/L，PLT\>100×109/L Hb\>10g/dL;Cr\<1.8mg/dL，bilirubin\<1.5mg/dL，GPT\<1.5 upper limit of normal * No vital systems dysfunction or malnutrition * No other malignant diseases in 5 years（except non melanoma or Cervical carcinoma in situ） * Have never accepted radiation therapy、overall chemotherapy or biotherapy * Know the whole protocol，Voluntary participate and sign a consent form Exclusion Criteria: * Tumor has violated the surrounding tissue organs（T4） * Preoperative have evidence of distant metastasis including the contralateral mediastinal lymph nodes * Arrhythmia need anti-arrhythmic treatment（except for β-blockers or digoxin），Symptomatic coronary artery disease and myocardial ischemia (myocardial infarction) in the past 6 months or more than NYHA class II congestive heart failure * Adverse drug control severe hypertension * Moderate to severe proteinuria * History of HIV infection or activity of chronic hepatitis b or hepatitis c, or other active clinical severe infection * Cachexy,organ function decompensation * History of chest radiotherapy * Not fully control the eye inflammation * Epilepsy patients needed treatment（such as Steroids or antiepileptic cure） * Interstitial pneumonia * Drug abuse and medical, psychological or social conditions may interfere with the patients involved in the research or have an impact on the results of evaluation * Known or suspected to study drug allergy or to give any drug allergies associated with this test * Any unstable situation or may endanger the patient safety and compliance * Fertility and pregnancy or lactation women, and have not been sufficient precautions